Powered by

New England Journal of Medicine publishes positive results of the pivotal trial of CabliviĀ® (caplacizumab) for rare blood clotting disorder

Jan 09, 2019 - PR Newswire

PR Newswire

The New England Journal of Medicine (NEJM)today published positive results of the Phase 3 trial of CabliviĀ® (caplacizumab) in adults with acquired thrombotic thrombocytopenic purpura (aTTP).

aTTP is a rare, life-threatening autoimmune blood disorder characterized by extensive clot formation in small blood vessels throughout the body, leading to severe thrombocytopenia (very low platelet count), microangiopathic hemolytic anemia (loss of red blood cells through destructio...